Surgical Interventions and Medical Treatments in Treatment-Naive Patients With Acromegaly: Systematic Review and Meta-Analysis

被引:45
作者
Abu Dabrh, Abd Moain [1 ,2 ]
Mohammed, Khaled [2 ]
Asi, Noor [2 ]
Farah, Wigdan H. [2 ]
Wang, Zhen [2 ]
Farah, Magdoleen H. [2 ]
Prokop, Larry J. [3 ]
Katznelson, Laurence [4 ,5 ]
Murad, Mohammad Hassan [1 ,2 ]
机构
[1] Mayo Clin, Div Prevent Occupat & Aerosp Med, Rochester, MN 55905 USA
[2] Mayo Clin, Ctr Sci Hlth Care Delivery, Knowledge & Evaluat Res Unit, Rochester, MN 55905 USA
[3] Mayo Clin, Lib Publ Serv, Rochester, MN 55905 USA
[4] Stanford Univ, Sch Med, Dept Med, Div Endocrinol & Metab, Stanford, CA 94305 USA
[5] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA
关键词
ENDOSCOPIC TRANSSPHENOIDAL SURGERY; SECRETING PITUITARY-ADENOMAS; NEWLY-DIAGNOSED PATIENTS; GROWTH-FACTOR-I; OCTREOTIDE-LAR; TUMOR SHRINKAGE; PRIMARY THERAPY; LONG-TERM; LANREOTIDE AUTOGEL; MODERN CRITERIA;
D O I
10.1210/jc.2014-2900
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Acromegaly is usually treated with surgery as a first-line treatment, although medical therapy has also been used as an alternative primary treatment. Objective: We conducted a systematic review and meta-analysis to synthesize the existing evidence comparing these two approaches in treatment-naive patients with acromegaly. Data Sources: This study performed a comprehensive search in multiple databases, including Medline, EMBASE, and Scopus from early inception through April 2014. Study Selection: The study used original controlled and uncontrolled studies that enrolled patients with acromegaly to receive either surgical treatment or medical treatment as their first-line treatment. Data Extraction: Reviewers extracted data independently and in duplicates. Because of the noncomparative nature of the available studies, we modified the Newcastle-Ottawa Scale to assess the quality of included studies. Outcomes evaluated were biochemical remission and change in IGF-1 or GH levels. We pooled outcomes using the random-effects model. Data Synthesis: The final search yielded 35 studies enrolling 2629 patients. Studies were noncomparative series with a follow-up range of 6-360 months. Compared with medical therapy, surgery was associated with a higher remission rate (67% vs 45%; P = .02). Surgery had higher remission rates at longer follow-up periods (>= 24 mo) (66% vs 44%; P = .04) but not the shorter follow-up periods (<= 6 mo) (53% vs 26%; P = .02). Surgery had higher remission rates in the follow-up levels of GH (65% vs 46%; P = .05). In one study, the IGF-1 level was reduced more with surgery compared with medical treatment (-731 mu g/L vs -251 mu g/L; P = .04). Studies in which surgery was performed by a single operator reported a higher remission rate than those with multiple operators (71% vs 47%; P = .002). Conclusions: Surgery may be associated with higher remission rate; however, the confidence in such evidence is very low due to the noncomparative nature of the studies, high heterogeneity, and imprecision.
引用
收藏
页码:4003 / 4014
页数:12
相关论文
共 44 条
[1]   Recent primary transnasal surgical outcomes associated with intraoperative growth hormone measurement in acromegaly [J].
Abe, T ;
Lüdecke, DK .
CLINICAL ENDOCRINOLOGY, 1999, 50 (01) :27-35
[2]  
Ahmed S, 1999, CLIN ENDOCRINOL, V50, P561
[3]   Outcome of multimodal therapy in operated acromegalic patients, a study in 115 patients [J].
Albarel, Frederique ;
Castinetti, Frederic ;
Morange, Isabelle ;
Conte-Devolx, Bernard ;
Gaudart, Jean ;
Dufour, Henry ;
Brue, Thierry .
CLINICAL ENDOCRINOLOGY, 2013, 78 (02) :263-270
[4]   Treatment of Elderly Acromegalics [J].
Arita, Kazunori ;
Hirano, Hirofumi ;
Yunoue, Shunji ;
Fujio, Shingo ;
Tominaga, Atsusi ;
Sakoguchi, Tetsuhiko ;
Sugiyama, Kazuhiko ;
Kurisu, Kaoru .
ENDOCRINE JOURNAL, 2008, 55 (05) :895-903
[5]   Octreotide Lar Affects the Volume of Pituitary Adenoma in Acromegalic Patients [J].
Baldys-Waligorska, A. ;
Krzentowska-Korek, A. ;
Golkowski, F. ;
Sokolowski, G. ;
Hubalewska-Dydejczyk, A. .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2011, 119 (05) :295-299
[6]   Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: Mortality, morbidity, and the effects of hospital and surgeon volume [J].
Barker, FG ;
Klibanski, A ;
Swearingen, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (10) :4709-4719
[7]   Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly [J].
Beauregard, C ;
Truong, U ;
Hardy, J ;
Serri, O .
CLINICAL ENDOCRINOLOGY, 2003, 58 (01) :86-91
[8]   Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size [J].
Bevan, JS ;
Atkin, SL ;
Atkinson, AB ;
Bouloux, PM ;
Hanna, F ;
Harris, PE ;
James, RA ;
McConnell, M ;
Roberts, GA ;
Scanlon, MF ;
Stewart, PM ;
Teasdale, E ;
Turner, HE ;
Wass, JAH ;
Wardlaw, JM .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (10) :4554-4563
[9]   AcroBel - the Belgian registry on acromegaly: a survey of the 'real-life' outcome in 418 acromegalic subjects [J].
Bex, Marie ;
Abs, Roger ;
T'Sjoen, Guy ;
Mockel, Lean ;
Velkeniers, Brigitte ;
Muermans, Katja ;
Maiter, Dominique .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2007, 157 (04) :399-409
[10]   Determinants of survival in treated acromegaly in a single center: Predictive value of serial insulin-like growth factor I measurements [J].
Biermasz, NR ;
Dekker, FW ;
Pereira, AM ;
van Thiel, SW ;
Schutte, PJ ;
van Dulken, H ;
Romijn, JA ;
Roelfsema, F .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (06) :2789-2796